Inventor · disambiguated record
Henrik Sune Andersen
Also filed as: ANDERSEN HENRIK · ANDERSEN HENRIK S · ANDERSEN HENRIK SUNE
63 granted patents·31 pending applications·1,382 citations·filing 1990–2020
99Inventor score
Files withNOVO NORDISK AS53HIGH POINT PHARMACEUTICALS LLC12NOVO NORDISK HEALTHCARE AG8KILBURN JOHN PAUL4EBDRUP SOREN3
Top patents by PatentIndex Score
94 records- 0197US7501405B2Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disordersHIGH POINT PHARMACEUTICALS LLC·Filed 2005·Granted Mar 10, 2009·55 cites·3 claims
- 0297US6410586B1Modulators of protein tyrosine phosphatases (PTPases)NOVO NORDISK AS·Filed 2001·Granted Jun 25, 2002·78 cites·7 claims
- 0397US5972978AModulators of molecules with phosphotyrosine recognition unitsNOVO NORDISK AS·Filed 1999·Granted Oct 26, 1999·96 cites·9 claims
- 0496US6262044B1Modulators of protein tyrosine phosphatases (PTPASES)NOVO NORDISK AS·Filed 1999·Granted Jul 17, 2001·108 cites·10 claims
- 0595US5958957AModulators of molecules with phosphotyrosine recognition unitsNOVO NORDISK AS·Filed 1997·Granted Sep 28, 1999·69 cites·10 claims
- 0693US7723323B2Pharmaceutical use of fused 1,2,4-triazolesHIGH POINT PHARMACEUTICALS LLC·Filed 2008·Granted May 25, 2010·32 cites·14 claims
- 0793US7358238B2Pharmaceutical use of fused 1,2,4-triazolesNOVO NORDISK AS·Filed 2005·Granted Apr 15, 2008·36 cites·9 claims
- 0892US8779109B2Growth hormones with prolonged in-vivo efficacyNOVO NORDISK HEALTHCARE AG·Filed 2013·Granted Jul 15, 2014·17 cites·11 claims
- 0990US7700583B211β-hydroxysteroid dehydrogenase type 1 active compoundsHIGH POINT PHARMACEUTICALS LLC·Filed 2005·Granted Apr 20, 2010·30 cites·17 claims
- 1088US6225329B1Modulators of protein tyrosine phosphatases (PTPases)NOVO NORDISK AS·Filed 1999·Granted May 1, 2001·58 cites·13 claims
- 1188US6080770AModulators of molecules with phosphotyrosine recognition unitsNOVO NORDISK AS·Filed 1999·Granted Jun 27, 2000·32 cites·9 claims
- 1286US8053431B2Pharmaceutical use of substituted amidesHIGH POINT PHARMACEUTICALS LLC·Filed 2006·Granted Nov 8, 2011·9 cites·8 claims
- 1385US8841249B2Growth hormones with prolonged in-vivo efficacyJOHANSEN NILS LANGELAND·Filed 2010·Granted Sep 23, 2014·9 cites·4 claims
- 1485US8053447B211β-hydroxysteroid dehydrogenase type 1 active compoundsHIGH POINT PHARMACEUTICALS LLC·Filed 2007·Granted Nov 8, 2011·7 cites·10 claims
- 1585US8048908B211β-hydroxysteroid dehydrogenase type 1 active compoundsHIGH POINT PHARMACEUTICALS LLC·Filed 2007·Granted Nov 1, 2011·4 cites·6 claims
- 1684US6410556B1Modulators of protein tyrosine phosphateses (PTPases)NOVO NORDISK AS·Filed 2000·Granted Jun 25, 2002·19 cites·77 claims
- 1783US7019026B1Modulators of Protein Tyrosine Phosphatases (PTPases)NOVO NORDISK AS·Filed 2000·Granted Mar 28, 2006·23 cites·74 claims
- 1883US6127343ASomatostatin agonists and antagonistsNOVO NORDISK AS·Filed 1997·Granted Oct 3, 2000·38 cites·17 claims
- 1983US6110913AN-substituted azaheterocyclic carboxylic acids and esters thereofNOVO NORDISK AS·Filed 1998·Granted Aug 29, 2000·53 cites·41 claims
- 2082US6796970B1Dose setting deviceNOVO NORDISK AS·Filed 1998·Granted Sep 28, 2004·238 cites·10 claims
- 2179US6063800AModulators of molecules with phosphotyrosine recognition unitsNOVO NORDISK AS·Filed 1999·Granted May 16, 2000·17 cites·9 claims
- 2278US6951878B2Benzo[b]thiophenyl or tetrahydro-benzo[b]thiophenyl modulators of protein tyrosine phosphatases (PTPases)NOVO NORDISK AS·Filed 2002·Granted Oct 4, 2005·7 cites·17 claims
- 2378US6613903B2Modulators of protein tyrosine phosphatases (PTPases)NOVO NORDISK AS·Filed 2001·Granted Sep 2, 2003·9 cites·21 claims
- 2477US8865868B2Conjugated proteins with prolonged in vivo efficacyBEHRENS CARSTEN·Filed 2009·Granted Oct 21, 2014·4 cites·9 claims
- 2577US5595989AN-substituted azaheterocyclic carboxylic acids and esters thereofNOVO NORDISK AS·Filed 1995·Granted Jan 21, 1997·24 cites·19 claims
- 2676US8153798B2Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitorsKILBURN JOHN PAUL·Filed 2007·Granted Apr 10, 2012·3 cites·4 claims
- 2776US8138342B211β-hydroxysteroid dehydrogenase type 1 active spiro compoundsKILBURN JOHN PAUL·Filed 2005·Granted Mar 20, 2012·3 cites·2 claims
- 2875US6071901ASubstituted dibenz[b,f]azepines and uses thereofNOVO NORDISK AS·Filed 1998·Granted Jun 6, 2000·20 cites·31 claims
- 2975US5688788AN-substituted azaheterocyclic carboxylic acids and esters thereofNOVO NORDISK AS·Filed 1995·Granted Nov 18, 1997·22 cites·15 claims
- 3075US2020102568A1Growth Hormones with Prolonged In-Vivo EfficacyNOVO NORDISK HEALTHCARE AG·Filed 2019·Application pending·0 cites
- 3174US7115624B1Method of inhibiting protein tyrosine phosphatase 1B and/or T-cell protein tyrosine phosphatase 4 and/or other PTPases with an Asp residue at position 48NOVO NORDISK AS·Filed 2000·Granted Oct 3, 2006·6 cites·6 claims
- 3273US9737612B2Antagonistic DR3 ligandsANDERSEN METTE DAHL·Filed 2012·Granted Aug 22, 2017·3 cites·17 claims
- 3371US2009264412A1Combination Therapy Using An 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor And A Glucocorticoid Receptor Agonist To Minimize The Side Effects Associated With Glucocorticoid Receptor Agonist TherapyHIGH POINT PHARMACEUTICALS LLC·Filed 2009·Application pending·0 cites
- 3470US9695226B2Growth hormones with prolonged in-vivo efficacyBEHRENS CARSTEN·Filed 2011·Granted Jul 4, 2017·1 cites·14 claims
- 3568US6239148B1N-substituted azaheterocyclic carboxylic acids and esters thereofNOVO NORDISK AS·Filed 1998·Granted May 29, 2001·11 cites·10 claims
- 3667US6004983AN-substituted azaheterocyclic compoundsNOVO NORDISK AS·Filed 1997·Granted Dec 21, 1999·24 cites·18 claims
- 3767US5874428AN-substituted aza-heterocyclic carboxylic acids and esters thereofNOVO NORDISK ALS·Filed 1996·Granted Feb 23, 1999·26 cites·23 claims
- 3866US2010120743A111Beta-Hydroxysteroid Dehydrogenase Type 1 Active CompoundsHIGH POINT PHARMACEUTICALS LLC·Filed 2009·Application pending·0 cites
- 3965US2020306382A1Growth Hormones with Prolonged In-Vivo EfficacyNOVO NORDISK HEALTHCARE AG·Filed 2020·Application pending·0 cites
- 4063US5961496ASyringe with tiltable nut for quick piston disengagementNOVO NORDISK AS·Filed 1998·Granted Oct 5, 1999·111 cites·5 claims
- 4163US2019203213A1Growth Hormones with Prolonged In-Vivo EfficacyNOVO NORDISK HEALTHCARE AG·Filed 2019·Application pending·0 cites
- 4262US6166009AN-substituted azaheterocyclic carboxylic acids and esters thereofNOVO NORDISK AS·Filed 1999·Granted Dec 26, 2000·7 cites·50 claims
- 4362US2008108598A1Pharmaceutical use of substituted amidesNOVO NORDISK AS·Filed 2008·Application pending·0 cites
- 4460US2006094699A1Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapyKAMPEN GITA CAMILLA T·Filed 2005·Application pending·0 cites
- 4560US2014329750A1Growth Hormones with Prolonged In-Vivo EfficacyNOVO NORDISK HEALTHCARE AG·Filed 2014·Application pending·0 cites
- 4659US9713644B2Antagonistic DR3 ligandsNOVO NORDISK AS·Filed 2014·Granted Jul 25, 2017·0 cites·27 claims
- 4759US2009137574A1Combination Therapy Using an 11Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor and an Antihypertensive Agent for the Treatment of Metabolic Syndrome and Related Diseases and DisordersNOVO NORDISK AS·Filed 2009·Application pending·0 cites
- 4858US2017239362A1Growth Hormones with Prolonged In-Vivo EfficacyNOVO NORDISK HEALTHCARE AG·Filed 2017·Application pending·0 cites
- 4957US8765130B2Antagonistic DR3 ligandsNOVO NORDISK AS·Filed 2013·Granted Jul 1, 2014·0 cites·23 claims
- 5057US6169087B1Modulators of protein tyrosine phosphatases (PTPases)NOVO NORDISK AS·Filed 1998·Granted Jan 2, 2001·16 cites·20 claims
Showing the top 50 of 94 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Henrik Sune Andersen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →